Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 8;13(1):1717–1735. doi: 10.1080/21655979.2021.2019873

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 7. — The effects of pyroptosis-related risk score on the efficacy of PD-1/L1 inhibitors. (a) The expressive differences of 6 ICs between high- and low-PR risk groups. (b-g) The expressive correlations between PR risk score and 6 ICs. (h-k) The differences in PR risk score between response- and non-response patients for PD-1/L1 inhibitors treatments. (m) The relationships between the expressions of 8 risk PRGs and the sensitivities (IC50) of multiple drugs. PR, pyroptosis-related; PRGs, pyroptosis-related genes; ICs, immune checkpoints; IC50, half maximal inhibitory concentration; ns, not significantly; *p < 0.05, **p < 0.01.